May 7, 2013
Clinical Success Rates for New Cancer Drugs Doubled from the Mid-1990s to Early-2000s
April 9, 2013
New Protocol Design Approaches Will Improve Clinical Trial Performance and Efficiency
March 12, 2013
Investigative Site Landscape Remains Highly Fragmented as the Number of Active Investigators Worldwide Reaches an All-time High
January 24, 2013
Companion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles
January 15, 2013
New Research from Tufts [CSDD] Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices
January 8, 2013
Drug Developers Need to More Fully Identify and Address Root Causes of R&D Inefficiency, According to Tufts Center for the Study
November 6, 2012
Extraneous Data Collected in Clinical Trials Cost Drug Developers $4 Billion to $6 Billion Annually
October 17, 2012
Contract Support and Technical Service Providers Expected to Play a Growing Role in Drug Development
September 5, 2012
Oncology Drugs Get Faster Approvals than Non-Oncology Drugs in U.S., But the Opposite is True in the EU
August 7, 2012
Drug Companies Are Teaming with Academic Medical Centers to Create New Medicines
July 10, 2012
U.S. Cancer Patients Get Faster Access to More Oncology Drugs than European Patients
April 26, 2012
Drug Companies Are Looking to Shorten Time to Early Clinical Development
January 26, 2012
Drug Company Executives Are Expanding Their Use of Strategic Partnerships
Jan. 17, 2012
Tufts [CSDD] Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates
Nov. 17, 2011
Tufts CSDD presents a Forum on the Impact of CER on Biopharmaceutical Innovation and Patient Access
Nov. 8, 2011
Number of Monoclonal Antibody Products in Development Continues to Increase
Sept. 13, 2011
Majority of Clinical Trial Protocols Are Amended, But One-Third of Those Changes Are Avoidable
July 19, 2011
Lack of Clinically Useful Diagnostics Hinder Growth in Personalized Medicines
March 8, 2011
U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily
January 27, 2011
Translational Science Expected to Play a Growing Role in Creating New Drugs
January 12, 2011
U.S. Healthcare Stakeholders Uncertain about Benefits of Risk Evaluation Program
Tufts Center for the
Study of Drug Development
Tufts University
75 Kneeland Street
Suite 1100
Boston, MA 02111
USA
Phone: 617-636-2170
Fax: 617-636-2425
E-mail: csdd@tufts.edu
Copyright © 2013
Tufts Center for the
Study of Drug Development
All Rights Reserved